{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:41:08Z","timestamp":1777934468679,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,7]]},"abstract":"\n Introduction<\/jats:title>\n As immune checkpoint inhibitors increasingly gain oncological utility, the incidence of unique adverse events may rise as well. The description and management of localized, recurrent muscle spasms secondary to pembrolizumab infusions has not previously been reported.<\/jats:p>\n <\/jats:sec>\n \n Case report<\/jats:title>\n A 64-year-old male receiving pembrolizumab infusions experienced acute-onset, isolated spasms and pain occurring in cycles 2 through 5. Management and outcome: Pretreatment with intravenous lorazepam, diphenhydramine, famotidine, ondansetron, and fluids have led to spasm-free pembrolizumab infusions.<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n The purpose of this report is to provide the first known incidence and successful corrective measures taken for localized muscle spasms secondary to pembrolizumab infusion.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/1078155220967094","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T01:02:48Z","timestamp":1604538168000},"page":"1270-1274","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Localized muscle spasm as a manifestation of pembrolizumab-induced infusion reaction"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3754-0057","authenticated-orcid":false,"given":"Christopher","family":"White","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Oregon Health & Science University, Portland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared","family":"Borlagdan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Oregon Health & Science University, Portland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Wing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Oregon Health & Science University, Portland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles D","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Portland, USA"},{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"bibr1-1078155220967094","volume-title":"Goodman & Gilman's: the pharmacological basis of therapeutics","author":"Wellstein A","year":"2017","edition":"13"},{"key":"bibr2-1078155220967094","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13895"},{"key":"bibr3-1078155220967094","unstructured":"Keytruda [package insert].\n Whitehouse Station\n , NJ: Merck Sharp & Dohme Corp, 2020."},{"key":"bibr4-1078155220967094","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.01.044"},{"key":"bibr5-1078155220967094","doi-asserted-by":"publisher","DOI":"10.1188\/10.CJON.E10-E21"},{"key":"bibr6-1078155220967094","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr7-1078155220967094","unstructured":"National Comprehensive Cancer Network (NCCN).\n NCCN Clinical Practice Guidelines in Oncology. Management of Immunotherapy-Related Toxicities Version 1.2020\n . 2019."},{"key":"bibr8-1078155220967094","unstructured":"Schmitte R.\n Adverse event reporting and supportive evidence\n , email communication, July 6, 2020."},{"key":"bibr9-1078155220967094","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091"},{"key":"bibr10-1078155220967094","author":"Baxi S","year":"2018","journal-title":"BMJ (Online)"},{"key":"bibr11-1078155220967094","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz189"},{"key":"bibr12-1078155220967094","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(94)90199-6"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220967094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220967094","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220967094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:01Z","timestamp":1777688641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220967094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1177\/1078155220967094"],"URL":"https:\/\/doi.org\/10.1177\/1078155220967094","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]}}}